Fresh off a high-energy showing at CPHI North America, the Olon USA and Olon Italy teams are keeping the momentum alive as we look ahead to one of the most anticipated events in our industry calendar: BIO International 2025 in Boston.
The pharmaceutical landscape is shifting rapidly, but for Olon, the course is clear. As we step into the second half of 2025, we’re focused, energized, and ready to continue supporting innovators across the development spectrum.
While our U.S. team will attend BIO International in Boston in a more targeted capacity, Olon SpA’s biotech division will bring a strong presence from Italy to this global event. Together, we’re showing up not just to exhibit, but to engage deeply with the future of drug development, in all its complexity and promise.
Focused Presence, Strategic Intent
After months of refining our mid-year strategy, BIO comes at the perfect time. The industry is navigating market uncertainty—regulatory ambiguity, shifting global investments, and a new calculus around risk management and supply chain security. Rather than pull back, Olon USA is doubling down on intentional, high-value conversations.
You won’t find us trying to win a popularity contest on the exhibit floor—you’ll find us talking with people who are actively advancing their drug programs and looking for real solutions.
Key Themes We’re Bringing to BIO
1. Dual-Site Supply Strategy: The Best of Both Worlds
Global volatility has only sharpened the need for flexible, redundant manufacturing models. With integrated capabilities in both India and the U.S., Olon offers a seamless path from early-phase efficiencies to GMP-certified final steps—balancing cost advantages with regulatory confidence.
“India is no longer just the lower-cost option—it’s becoming the more stable option in some respects.”
– Robert Poe, Olon USA
For clients rethinking their sourcing models in light of tariffs, funding uncertainties, or geopolitical risk, our dual-site model provides clarity, stability, and speed.
2. Integrated CMC Partnerships: A United Front
Through strategic collaboration with partners like Ascendia Pharmaceutical Solutions, Olon is helping early-stage companies manage the entire CMC journey—from API to drug product—with fewer handoffs, more transparency, and stronger alignment.
The response from emerging biotech teams has been clear: they want fewer vendors and more strategic partners. We’re answering that call.
3. Onshoring and Risk Reduction
From tech transfers to early-stage synthesis, more clients are looking to reallocate manufacturing to U.S. soil—and they’re not waiting for another disruption to make the move.
“Clients are asking: ‘What if I lose access to a foreign site overnight?’ They’re proactively building redundancy, and Olon is in a great position to provide it.”
– Kyle P. Kalbarczyk, Ph.D.
Our ability to scale between global and domestic options, without compromising timelines or cost-effectiveness, is a true differentiator in today’s market.
Why Meet with Olon USA at BIO?
We’re not just another CDMO. We’re a solutions-focused, globally equipped, and strategically aligned partner ready to support your molecule’s journey—wherever it needs to go next.
Whether you’re:
- Exploring new synthesis routes or bio fermentation
- Navigating policy shifts,
- Building a fully integrated CMC solution, or
- Looking for risk-adjusted global manufacturing support—
Olon USA is ready to talk.
Let’s meet at BIO and shape what’s next, together.
Connect with us ahead of BIO to schedule a targeted conversation with our U.S./Italy team, or find us on-site at Booth 3178. Either way, we’re here to keep your molecule moving forward with clarity, confidence, and a commitment to quality.